1
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
Condition(s):Hodgkin LymphomaLast Updated:May 10, 2023Active, not recruiting
Nivolumab: 1744 Clinical Trials, Page 1 of 175
Hide Studies Not Open or Pending
2
WGA in Platinum-refractory HNSCC Underwent Nivolumab
Condition(s):HNSCCLast Updated:April 25, 2019Unknown status
3
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
Condition(s):Hodgkin LymphomaLast Updated:June 9, 2023Completed
4
Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer.
Condition(s):Metastatic Pancreatic CancerLast Updated:July 18, 2023Terminated
5
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
Condition(s):Hematologic MalignanciesLast Updated:June 25, 2020Terminated
6
Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer
Condition(s):Kidney Cancer; Lung CancerLast Updated:November 12, 2019Completed
7
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Condition(s):Aml; AML, AdultLast Updated:October 12, 2020Withdrawn
8
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
Condition(s):Renal Cell Cancer Metastatic; Non-small Cell Lung Cancer Metastatic; Pleural Effusion, MalignantLast Updated:March 8, 2023Completed
9
NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN
Condition(s):Squamous Cell Carcinoma of Head and NeckLast Updated:April 6, 2023Completed
10
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
Condition(s):Head and Neck CancerLast Updated:October 4, 2022Active, not recruiting